This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
相关报告
2023年一季度中国经济观察
3803
类型:宏观
上传时间:2023-02
标签:2023Q1、经济)
语言:中文
金额:5积分
-2023年Q1中国新经济创业投资数据分析报告
1539
类型:专题
上传时间:2023-04
标签:2023Q1、新经济、创业投资)
语言:中文
金额:5积分
2023年第一季度中国上市银行业绩分析:固本培元,展骐骥之跃
1248
类型:行研
上传时间:2023-06
标签:上市、银行、2023Q1)
语言:中文
金额:5积分
2023第一季度跨境电商行业趋势报告-雨果跨境
860
类型:行研
上传时间:2023-04
标签:跨境电商、2023Q1)
语言:中文
金额:免费
中国宏观金融分析-2023年第一季度
858
类型:宏观
上传时间:2023-04
标签:宏观金融、2023Q1、经济)
语言:中文
金额:5积分
消费品零售业2023年第一季度报告
725
类型:行研
上传时间:2023-07
标签:消费品、零售、2023Q1)
语言:中文
金额:5积分
智库-2023年第一季度中国宏观经济分析报告
689
类型:宏观
上传时间:2023-05
标签:2023Q1、宏观经济、经济复苏)
语言:中文
金额:5积分
2023第一季度中国数字科技人才流动报告
645
类型:行研
上传时间:2023-04
标签:数字科技、人才、2023Q1)
语言:中文
金额:5积分
中国家庭财富变动趋势(2023年1季度)——中国家庭财富指数调研系列报告
623
类型:专题
上传时间:2023-05
标签:2023Q1、家庭财富、中国)
语言:中文
金额:5积分
2023第一季度中国内地及香港IPO市场回顾与前景展望
622
类型:专题
上传时间:2023-04
标签:2023Q1、IPO、资本市场)
语言:中文
金额:5积分
积分充值
30积分
6.00元
90积分
18.00元
150+8积分
30.00元
340+20积分
68.00元
640+50积分
128.00元
990+70积分
198.00元
1640+140积分
328.00元
微信支付
余额支付
积分充值
应付金额:
0 元
请登录,再发表你的看法
登录/注册